Skip to main content

Amgen company profile

  • AMGN · Nasdaq
  • Biotechnology
  • S&P 500
$465.67−0.30%Close 13 Nov 2026 · Market value $253.3B

About Amgen

Amgen Inc. discovers, develops, manufactures and delivers biologic and small molecule medicines for serious diseases, with a stated focus on areas of high unmet medical need. Its marketed products include Prolia, XGEVA, Repatha, Otezla, ENBREL, EVENITY, TEPEZZA, BLINCYTO, Nplate, TEZSPIRE, KYPROLIS, Aranesp, KRYSTEXXA and Vectibix, along with biosimilar products. Its customers include healthcare providers, dialysis centers, hospitals and pharmacies, and in the United States it sells principally to pharmaceutical wholesale distributors. The largest concentration of its sales and marketing operations is in the United States and Europe, and it markets products in approximately 100 countries. Manufacturing is performed at facilities in the United States, Ireland, the Netherlands and Singapore, and distribution centers operate in Puerto Rico, Kentucky, California and the Netherlands.

A summary of the business section of the company's latest annual report, filed 13 Feb 2026.

Company facts

TickerAMGN · Nasdaq
SectorBiotechnology
IndustryBiotechnology
IndexS&P 500
Fiscal year ends31 December
Reporting currencyUSD
CIK318154
Latest annual report10-K, filed 13 Feb 2026

Officers and directors

NameRoleShares ownedLatest Form 4
Robert A. BradwayChairman, CEO and President · Director1.5M · < 1%Shares withheld for tax, 7 May 2026
Murdo GordonEVP, Global Commercial Ops225K · < 1%Shares withheld for tax, 7 May 2026
David M. ReeseEVP & Chief Technology Officer225K · < 1%Shares withheld for tax, 7 May 2026
Peter H. GriffithEVP & CFO170K · < 1%Shares withheld for tax, 7 May 2026
James E. BradnerEVP, Research and Development18.5K · < 1%Shares withheld for tax, 7 May 2026
Greg C. GarlandDirector13.2K · < 1%Grant or award, 19 May 2026
Robert A. EckertDirector8.0K · < 1%Grant or award, 19 May 2026
Wanda M. AustinDirector7.4K · < 1%Grant or award, 19 May 2026
Tyler JacksDirector3.4K · < 1%Grant or award, 19 May 2026
Brian J. DrukerDirector3.2K · < 1%Grant or award, 19 May 2026
Charles M. Holley, Jr.Director1.3K · < 1%Grant or award, 7 Aug 2026
S. Omar IshrakDirector935 · < 1%Grant or award, 7 Aug 2026
Mary E. KlotmanDirector719 · < 1%Grant or award, 19 May 2026
Ellen J. KullmanDirector410 · < 1%Grant or award, 19 May 2026
Amy E. MilesDirector408 · < 1%Grant or award, 19 May 2026
Khosla RachnaSVP, Business Development—Open-market sale, 13 Aug 2026
Michael V. DrakeDirector—Grant or award, 7 Aug 2026
Busch Matthew C.VP, Finance & CAO—Grant or award, 7 Aug 2026
Miller DerekSVP, Human Resources—Open-market sale, 6 Aug 2026
Grygiel Nancy A.SVP & CCO—Open-market sale, 6 Aug 2026

Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.

AMGN in the terminal

The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.